Wire · opportunities
CAR T-Cell Therapy Tops Bispecific Antibodies in Relapsed MCL
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 October 2026 · Fusion42 review
A meta-analysis shows CAR T-cell therapy yields higher complete response rates than bispecific antibodies in relapsed/refractory mantle cell lymphoma, though durability of responses remains unclear due to lack of randomized head-to-head trials.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You need to prepare for CAR T-cell therapies setting a new standard for relapsed mantle cell lymphoma treatment as payers and clinicians await durability data for these competing options. Watch trial developments closely to identify early access or partnership opportunities before randomized comparisons reshape patient care.
◆ Coverage
1 source · 13 Oct 2026
◆ Related on Wire
◆ Topics